DOCSLIB.ORG

Therapeutic Strategies for Recent Hepatitis C Virus Infection in the Era of Direct-Acting Antiviral Therapy

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Therapeutic Strategies for Recent Hepatitis C Virus Infection in the Era of Direct-Acting Antiviral Therapy Therapeutic strategies for recent hepatitis C virus infection in the era of direct-acting antiviral therapy Marianne Martinello A thesis in fulfilment of the requirements for the degree of Doctor of Philosophy The Kirby Institute Faculty of Medicine May 2017 Page 1 of 309 Thesis/Dissertation Sheet THE UNIVERSITY OF NEW SOUTH WALES Thesis/Dissertation Sheet Surname or Family name: Martinello First name: Marianne Abbreviation for degree as given in the University calendar: PhD School: Kirby Institute Faculty: Medicine Title: Therapeutic strategies for recent hepatitis C virus infection in the era of direct-acting antiviral therapy Abstract: Background: The management of recent hepatitis C virus (HCV) infection is uncertain, as the therapeutic landscape evolves with the advent of direct-acting antiviral (DAA) therapy. Aims: The broad aim of this research was to examine novel therapeutic strategies in recent HCV following the availability of DAA therapy. Specific aims included assessing the feasibility, efficacy and safety of response-guided interferon (IFN) -containing and ultra-short IFN-free therapy; calculating reinfection incidence following treatment; and determining the clinical significance of drug-drug interactions in HIV/HCV co-infection. Methods: In Chapters Two and Three, the efficacy and safety of short and/or response-guided treatment among individuals with recent HCV was examined in three open-label trials: ATAHC II (n=52; pegylated-IFN +/- ribavirin), DARE-C I (n=14; pegylated-IFN, ribavirin + telaprevir) and DARE-C II (n=19; sofosbuvir + ribavirin). In Chapter Four, reinfection incidence following treatment for recent HCV was calculated among those who achieved an end-of-treatment response in ATAHC I and II, DARE-C I and II (n=120). In Chapter Five, a simulation of potential drug-drug interactions between combination antiretroviral therapy and DAAs was performed in those with HIV/HCV enrolled in CEASE-D (n=257). Page 2 of 309 Key Findings: A total of 85 individuals (73% HIV) with recent HCV commenced short and/or response-guided treatment between 2010 and 2015; none of the strategies trialled was optimal. Given toxicity, the applicability of an IFN-containing strategy is limited. Conversely, six weeks of sofosbuvir and ribavirin was safe and well tolerated, but efficacy was poor. High reinfection incidence, particularly in individuals reporting injection drug use following treatment, was seen. These trials confirmed the feasibility of short duration therapy in recent HCV and informed contemporary trial design. Optimal DAA regimen choice for future research will be crucial; the combination of a nucleotide analogue and an NS5A inhibitor appears appropriate given potency and little potential for drug-drug interactions in HIV/HCV co-infection. Conclusion: The role and efficacy of ultra-short duration therapy in recent HCV requires further evaluation with potent DAA regimens. The significant risk for HCV reinfection following treatment in individuals with ongoing behaviour facilitating transmission emphasises the need for post-treatment surveillance, harm reduction strategies and education. Declaration relating to disposition of project thesis/dissertation I hereby grant to the University of New South Wales or its agents the right to archive and to make available my thesis or dissertation in whole or in part in the University libraries in all forms of media, now or here after known, subject to the provisions of the Copyright Act 1968. I retain all property rights, such as patent rights. I also retain the right to use in future works (such as articles or books) all or part of this thesis or dissertation. I also authorise University Microfilms to use the 350 word abstract of my thesis in Dissertation Abstracts International (this is applicable to doctoral theses only). 14 Dec 2016 Signature Witness Date The University recognises that there may be exceptional circumstances requiring restrictions on copying or conditions on use. Requests for restriction for a period of up to 2 years must be made in writing. Requests for a longer period of restriction may be considered in exceptional circumstances and require the approval of the Dean of Graduate Research. FOR OFFICE USE ONLY Date of completion of requirements for Award: Page 3 of 309 Contents Thesis/Dissertation Sheet .............................................................................................................. 2 Supervisor Statement .................................................................................................................... 8 Originality Statement .................................................................................................................... 9 Copyright Statement ................................................................................................................... 10 Authenticity Statement ................................................................................................................ 11 Acknowledgements ..................................................................................................................... 12 List of publications and presentations ......................................................................................... 14 Publications ............................................................................................................................. 14 Conference presentations ........................................................................................................ 15 Abbreviations .............................................................................................................................. 17 Chapter 1 Introduction and Literature Review............................................................................ 19 Epidemiology of recent HCV infection .................................................................................. 19 HCV incidence and risk factors for acquisition .................................................................. 20 Detection of acute HCV infection ....................................................................................... 27 Management of acute and recent HCV infection .................................................................... 29 Natural history and spontaneous clearance ......................................................................... 29 Timing of HCV treatment initiation .................................................................................... 30 Interferon-based treatment of acute HCV mono-infection ................................................. 30 Interferon-based treatment of recent HCV infection in PWID ........................................... 32 Interferon-based treatment of recent HCV infection in HIV co-infection .......................... 32 Duration of interferon-based treatment in recent HCV infection ....................................... 33 Evidence gaps related to the treatment of acute and recent HCV infection ........................ 33 Overview of Protease, Polymerase and Assembly Inhibitors for the Treatment of HCV....... 35 Mechanism of drug action................................................................................................... 38 Mode of drug administration and dosage ............................................................................ 42 Adverse reactions and toxicity ............................................................................................ 46 Direct-acting antiviral efficacy in chronic HCV infection among PWID and people with HIV/HCV coinfection ............................................................................................................. 52 Evidence from clinical trials ............................................................................................... 52 Evidence from “real world” cohorts ................................................................................... 57 Reinfection following HCV treatment .................................................................................... 58 Who is at “high-risk” of reinfection? Defining the population of interest .......................... 58 HCV reinfection among people who inject drugs ............................................................... 61 HCV reinfection among HIV-positive MSM ...................................................................... 62 Mathematical modelling: Treatment-as-Prevention and the impact of reinfection ............. 63 Thesis rationale and objectives ............................................................................................... 65 Chapter 2 The efficacy, safety and feasibility of response-guided interferon-based therapy in recent HCV infection .................................................................................................................. 67 Chapter Introduction and Objectives ...................................................................................... 67 Page 4 of 309 Declaration .............................................................................................................................. 69 Co-authorship Acknowledgement........................................................................................... 70 Short duration response-guided treatment is effective for most individuals with recent hepatitis C infection: the ATAHC II and DARE-C I studies .................................................. 71 Abstract ..................................................................................................................................
Load more

Recommended publications
  • Treatment Program Policy Analysis 2017
    Public Disclosure Authorized Public Disclosure Authorized Public Disclosure Authorized Public Disclosure Authorized Treatment Program Analysis Treatment Policy PROGRAM Egypt’s Viral Hepatitis Program Treatment Program Policy Analysis 2017 This report is developed as part of the World Bank’s Technical Assistance on Strengthening Egypt’s Response to Viral Hepatitis. Comments and suggestions concerning the report contents are encouraged and could be sent to [email protected] 2 © 2017 International Bank for Reconstruction and Development / The World Bank 1818 H Street NW Washington DC 20433 Telephone: 202 473 1000 Internet: www.worldbank.org This work is a product of the staff of The World Bank with external contributions. The findings, interpretations, and conclusions expressed in this work do not necessarily reflect the views of The World Bank, its Board of Executive Directors, or the governments they represent. The World Bank does not guarantee the accuracy of the data included in this work. The boundaries, colors, denominations, and other information shown on any map in this work do not imply any judgment on the part of The World Bank concerning the legal status of any territory or the endorsement or acceptance of such boundaries. Rights and Permissions The material in this work is subject to copyright. Because The World Bank encourages dissemination of its knowledge, this work may be reproduced, in whole or in part, for noncommercial purposes as long as full attribution to this work is given. Any queries on rights and licenses, including subsidiary rights, should be addressed to the Office of the Publisher, The World Bank, 1818 H Street NW, Washington, DC 20433, USA; fax: 202 522 2422; e-mail: [email protected].
    [Show full text]
  • Development of Novel Antiviral Therapies for Hepatitis C Virus Kai Lin** (Novartis Institutes for Biomedical Research, Inc
    VIROLOGICA SINICA, August 2010, 25 (4):246-266 DOI 10.1007/s12250-010-3140-2 © Wuhan Institute of Virology, CAS and Springer-Verlag Berlin Heidelberg 2010 Development of Novel Antiviral Therapies for Hepatitis C Virus Kai Lin** (Novartis Institutes for BioMedical Research, Inc. Cambridge, Massachusetts 02139, USA) Abstract: Over 170 million people worldwide are infected with hepatitis C virus (HCV), a major cause of liver diseases. Current interferon-based therapy is of limited efficacy and has significant side effects and more effective and better tolerated therapies are urgently needed. HCV is a positive, single-stranded RNA virus with a 9.6 kb genome that encodes ten viral proteins. Among them, the NS3 protease and the NS5B polymerase are essential for viral replication and have been the main focus of drug discovery efforts. Aided by structure-based drug design, potent and specific inhibitors of NS3 and NS5B have been identified, some of which are in late stage clinical trials and may significantly improve current HCV treatment. Inhibitors of other viral targets such as NS5A are also being pursued. However, HCV is an RNA virus characterized by high replication and mutation rates and consequently, resistance emerges quickly in patients treated with specific antivirals as monotherapy. A complementary approach is to target host factors such as cyclophilins that are also essential for viral replication and may present a higher genetic barrier to resistance. Combinations of these inhibitors of different mechanism are likely to become the essential components of future HCV therapies in order to maximize antiviral efficacy and prevent the emergence of resistance.
    [Show full text]
  • Ascletis Pharma Inc. 歌禮製藥有限公司 (Incorporated in the Cayman Islands with Limited Liability) (Stock Code: 1672)
    Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement. This announcement contains forward-looking statements that involve risks and uncertainties. All statements other than statements of historical fact are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, some of which are beyond the Company’s control, that may cause the actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Ascletis Pharma Inc. 歌禮製藥有限公司 (Incorporated in the Cayman Islands with limited liability) (Stock Code: 1672) ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2019 The Board of Directors is pleased to announce the audited condensed consolidated annual results of the Group for the year ended December 31, 2019, together with the comparative figures for the corresponding period in 2018 as follows. FINANCIAL HIGHLIGHTS Year ended December 31, 2019 2018 Changes RMB’000 RMB’000
    [Show full text]
  • A Rational Approach to Identifying Effective Combined Anticoronaviral Therapies Against Feline 2 Coronavirus 3 4 5 S.E
    bioRxiv preprint doi: https://doi.org/10.1101/2020.07.09.195016; this version posted July 9, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. 1 A rational approach to identifying effective combined anticoronaviral therapies against feline 2 coronavirus 3 4 5 S.E. Cook1*, H. Vogel2, D. Castillo3, M. Olsen4, N. Pedersen5, B. G. Murphy3 6 7 1 Graduate Group Integrative Pathobiology, School of Veterinary Medicine, University of 8 California, Davis, CA, USA 9 10 2School of Veterinary Medicine, University of California, Davis, Ca, USA 11 12 3Department of Pathology, Microbiology, and Immunology, School of Veterinary Medicine, 13 University of California, Davis, CA, USA 14 15 4Department of Pharmaceutical Sciences, College of Pharmacy-Glendale, Midwestern 16 University, Glendale, AZ, USA 17 18 5Department of Medicine and Epidemiology, School of Veterinary Medicine, University of 19 California, Davis, CA, USA 20 21 22 *Corresponding author 23 24 E-mail: [email protected] (SEC) 25 26 27 Abstract 28 Feline infectious peritonitis (FIP), caused by a genetic mutant of feline enteric coronavirus 29 known as FIPV, is a highly fatal disease of cats with no currently available vaccine or FDA- 30 approved cure. Dissemination of FIPV in affected cats results in a range of clinical signs 31 including cavitary effusions, anorexia, fever and lesions of pyogranulomatous vasculitis and 32 peri-vasculitis with or without central nervous system and/or ocular involvement.
    [Show full text]
  • Reviews in Basic and Clinical Gastroenterology
    GASTROENTEROLOGY 2010;138:447–462 REVIEWS IN BASIC AND CLINICAL GASTROENTEROLOGY REVIEWS IN BASIC AND CLINICAL John P. Lynch and David C. Metz, Section Editors GASTROENTEROLOGY Resistance to Direct Antiviral Agents in Patients With Hepatitis C Virus Infection CHRISTOPH SARRAZIN and STEFAN ZEUZEM J. W. Goethe-University Hospital, Medizinische Klinik 1, Frankfurt am Main, Germany Chronic hepatitis C virus (HCV) infection is one of agents that are also named specific, targeted antiviral the major causes of cirrhosis, hepatocellular carci- therapies (STAT-C) for HCV infection are in phase 1–3 noma, and liver failure that leads to transplantation. trials. We review resistance to DAA agents, focusing on The current standard treatment, a combination of compounds in development such as reagents that target pegylated interferon alfa and ribavirin, eradicates the the HCV nonstructural (NS)3 protease, the NS5A pro- virus in only about 50% of patients. Directly acting tein, and the RNA-dependent RNA polymerase NS5B. We antiviral (DAA) agents, which inhibit HCV replica- also discuss indirect inhibitors or compounds that in- tion, are in phase 1, 2, and 3 trials; these include hibit HCV replication by not yet completely resolved reagents that target the nonstructural (NS)3 protease, mechanisms, such as cyclophilin inhibitors, nitazox- the NS5A protein, the RNA-dependent RNA-polymer- anide, and silibinin (Table 1, Figure 1). ase NS5B, as well as compounds that directly inhibit HCV replication through interaction with host cell Parameters That Affect Resistance proteins. Because of the high genetic heterogeneity of Heterogeneity of HCV HCV and its rapid replication, monotherapy with HCV has a high rate of turnover; its half-life was DAA agents poses a high risk for selection of resistant estimated to be only 2–5 hours, with the production and variants.
    [Show full text]
  • WO 2012/158271 Al 22 November 2012 (22.11.2012) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2012/158271 Al 22 November 2012 (22.11.2012) P O P C T (51) International Patent Classification: (74) Agent: PINO, Mark, J.; Connolly Bove Lodge & Hutz C07D 417/04 (2006.01) A61K 31/542 (2006.01) LLP, 1875 Eye Street, Nw, Suite 1100, Washington, DC C07D 513/04 (2006.01) A61P 31/14 (2006.01) 20006 (US). A61K 31/5415 (2006.01) (81) Designated States (unless otherwise indicated, for every (21) International Application Number: kind of national protection available): AE, AG, AL, AM, PCT/US20 12/032297 AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (22) International Filing Date: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, 5 April 2012 (05.04.2012) HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, (25) Filing Language: English KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (26) Publication Language: English OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, (30) Priority Data: SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, 61/472,286 6 April 201 1 (06.04.201 1) US TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (71) Applicant (for all designated States except US) : ANADYS (84) Designated States (unless otherwise indicated, for every PHARMACEUTICALS, INC.
    [Show full text]
  • Affordable Treatment Approaches for HCV with Sofosbuvir Plus
    Hepatitis C Dr. Graciela Diap-MD, Access HCV 18th International Congress on Infectious Diseases (ICID) - XIII Congreso SADI Buenos Aires, Argentina March 1-4, 2018 Origins of DNDi 1999 • First meeting to describe the lack of R&D for neglected diseases • MSF commits the Nobel Peace Prize money to the DND Working Group • JAMA article: ‘Access to essential drugs in poor countries - A Lost Battle?’ July 2003 • Creation of DNDi • Founding partners: • Institut Pasteur, France • Indian Council of Medical Research, India • Kenya Medical Research Institute, Kenya • Médecins Sans Frontières • Ministry of Health, Malaysia • Oswaldo Cruz Foundation/Fiocruz, Brazil • WHO –TDR (Special Programme for Research and Training in Tropical Diseases) as a permanent observer • ISID-SADI 2018 Buenos Aires Responding to the Needs of Neglected Patients MSF - Khan Sleeping Hepatitis C Sa'adia sickness © Mycetoma DNDi’s PRIORITY: Malaria Neglected Patients Chagas Paediatr disease ic HIV Leishmaniasis Filarial diseases …from Bench to Bedside • ISID-SADI 2018 Buenos Aires DNDi-HCV strategic objectives: Severe Disease • Develop new, affordable, pan- genotypic TT for HCV • Simplify HCV test & treat strategies and develop innovative models of care to support scale up • Improve access (IP, regulatory, pricing, etc.) and affordability of HCV TT in countries Minimal Disease • ISID-SADI 2018 Buenos Aires DNDi Hepatitis C Strategy: 3 pillars 2 3 1 Simplify Accelerate Catalyse TREATMENT R&D ACCESS STRATEGIES Accelerating the development Working with health Supporting affordable
    [Show full text]
  • Autophagy, Unfolded Protein Response, and Neuropilin-1 Cross-Talk in SARS-Cov-2 Infection: What Can Be Learned from Other Coronaviruses
    International Journal of Molecular Sciences Review Autophagy, Unfolded Protein Response, and Neuropilin-1 Cross-Talk in SARS-CoV-2 Infection: What Can Be Learned from Other Coronaviruses Morvarid Siri 1 , Sanaz Dastghaib 2 , Mozhdeh Zamani 1 , Nasim Rahmani-Kukia 3 , Kiarash Roustai Geraylow 4 , Shima Fakher 3, Fatemeh Keshvarzi 3, Parvaneh Mehrbod 5 , Mazaher Ahmadi 6 , Pooneh Mokarram 1,3,* , Kevin M. Coombs 7 and Saeid Ghavami 1,8,9,* 1 Autophagy Research Center, Shiraz University of Medical Sciences, Shiraz 7134845794, Iran; [email protected] (M.S.); [email protected] (M.Z.) 2 Endocrinology and Metabolism Research Center, Shiraz University of Medical Sciences, Shiraz 7193635899, Iran; [email protected] 3 Department of Biochemistry, Shiraz University of Medical Sciences, Shiraz 7134845794, Iran; [email protected] (N.R.-K.); [email protected] (S.F.); [email protected] (F.K.) 4 Student Research Committee, Semnan University of Medical Sciences, Semnan 3514799422, Iran; [email protected] 5 Influenza and Respiratory Viruses Department, Pasteur Institute of Iran, Tehran 1316943551, Iran; [email protected] 6 Faculty of Chemistry, Bu-Ali Sina University, Hamedan 6517838695, Iran; [email protected] 7 Department of Medical Microbiology and Infectious Diseases, Rady Faculty of Health Sciences, Max Rady Citation: Siri, M.; Dastghaib, S.; College of Medicine, University of Manitoba, Winnipeg, MB R3E 0J9, Canada; [email protected] Zamani, M.; Rahmani-Kukia, N.; 8 Department of Human Anatomy and Cell Science, Rady Faculty of Health Sciences, Max Rady College Geraylow, K.R.; Fakher, S.; Keshvarzi, of Medicine, University of Manitoba, Winnipeg, MB R3E 0J9, Canada F.; Mehrbod, P.; Ahmadi, M.; 9 Faculty of Medicine, Katowice School of Technology, 40-555 Katowice, Poland Mokarram, P.; et al.
    [Show full text]
  • Tuesday 6 June
    Tuesday 6 June 14:00- Registration at the Conference Venue 18:00 19:00- Opening ceremony, welcome reception and dinner 22:00 Wednesday 7 June 08:00- Registration 08:45 08:45- Welcome and Introduction 09:00 09:00- Benefit-risk profile of medicinal Chair: Oscar 10:30 products Della Pasqua Overview and implementation of multi criteria 09:00- Praveen decision analysis (MCDA) for benefit-risk 09:30 Thokala assessment European regulatory views on benefit-risk 09:30- Andreas assessment methodologies - role of MCDA and 10:00 Kouroumalis other model-based approaches Current practices and gaps in benefit-risk 10:00- Kevin Marsh assessment: opportunities for combining MCDA 10:30 with model-based approaches 10:30- Coffee break, Poster and Software session I 12:00 Page | 1 Posters in Group I (with poster numbers starting with I-) are accompanied by their presenter 12:00- Benefit-risk profile of medicinal Chair: Mats 12:40 products, continued Karlsson 12:00- Neeraj Model-Informed Drug Development (MIDD) for 12:20 Gupta ixazomib, an oral proteasome inhibitor Simulation analysis of absolute lymphocytes 12:20- Nadia counts (ALC) and relapse rate (RR) following 12:40 Terranova cladribine (re-)treatment rules in subjects with relapsing-remitting multiple sclerosis (RRMS) 12:40- Announcement for ACoP8 (2017) Jin Jin 12:45 12:45- Lunch 14:10 14:10- Chair: Lutz Scaling of PD in paediatrics 15:10 Harnisch Scaling pharmacodynamics in children: Lessons 14:10- Joseph from immunology, infectious diseases and 14:50 Standing critical care Scaling renal function in
    [Show full text]
  • HCV Treatment • Characteristics of DAA Classes
    HCV UPDATE Treatment: The Next Wave Access: Myths & Facts NASTAD National Technical Assistance Meeting October 2015 Tracy Swan HCV Treatment • Characteristics of DAA Classes • Next-generation: FDCs • Trends: 3somes and Quickies • HCV Treatment in HIV/HCV DAA CLASSES NON-NUCLEOSIDE POLYMERASE INHIBITORS (Dasabuvir): G1 only, further development/need?? PROTEASE INHIBITORS (Paritaprevir/r, Olysio): Usually G1 and G4, tendency for DDIs, possibly more side effects, resistance may not always be persistent—next generation might be pan-genotypic DAA CLASSES NS5A INHIBITORS (Daclatasvir, Ledipasvir, Ombitasvir, Velpatasvir) : pan/multi-genotypic (less information in G4, G5 and G6)—some DDIs, resistance can persist for >2 years stop them from working--next generation more potent, active against resistance? NUCLEOSIDE/TIDE POLYMERASE INHIBITORS (Sofosbuvir): pan/multi-genotypic (less information in G4, G5 and G6), few DDIs, resistance does not seem to be a major problem; a few more are finally in development Fixed-Dose Combinations (FDCs) WHAT’S HERE NOW…. Sofosbuvir + Ledipasvir Paritaprevir/r + Ombitasvir, w/ Dasabuvir WHAT’S COMING in 2016…. Grazoprevir + Elbasvir Sofosbuvir+ Velpatasvir What’s Coming in 2016 once daily DAA fixed-dose combinations, 12 weeks* Grazoprevir/Elbasvir adults w/ G 1,4 and 6 (TX- naive or -experienced, HIV/HCV; in people w/ cirrhosis or ESRD, and w/OST) ---cure rates generally >90% Sofosbuvir/Velpatasvir adults with all HCV genotypes (TX-naive or -experienced, people with cirrhosis) ---cure rates generally >90% *some
    [Show full text]
  • HCV Eradication with Direct Acting Antivirals (Daas)?
    HCV eradication with direct acting antivirals (DAAs)? Emilie Estrabaud Service d’Hépatologie et INSERM UMR1149, AP-HP Hôpital Beaujon, Paris, France. [email protected] HCV eradication with direct acting antivirals (DAAs)? HCV replication HCV genome and DAAs targets NS3 inhibitors NS5A inhibitors NS5B inhibitors Take home messages HCV viral cycle Asselah et al. Liver Int. 2015;35 S1:56-64. Direct acting antivirals 5’NTR Structural proteins Nonstructural proteins 3’NTR Metalloprotease Envelope Serine protease Glycoproteins RNA Capsid RNA helicase Cofactors Polymerase C E1 E2 NS1 NS2 NS3 NS4A NS4B NS5A NS5B Protease Inhibitors NS5A Inhibitors Polymerase Inhibitors Telaprevir Daclatasvir Nucs Non-Nucs Boceprevir Ledipasvir Simeprevir ABT-267 Sofosbuvir ABT-333 Faldaprevir GS-5816 VX-135 Deleobuvir Asunaprevir Direct Acting Antivirals: 2015 Asselah et al. Liver Int. 2015;35 S1:56-64. Genetic barrier for HCV direct acting antivirals High Nucleos(t)ide 1 mutation= high cost to Analog Inhibitors fitness, 2-3 additional mutations to increase fitness 2 st generation Protease Inhibitors n Non Nucleos(t)ide Analog Inhibitors : NS5 A Inhibitors 1 st generation Protease Inhibitors 1 mutation= low cost to fitness Low Halfon et al. J Hepatol 2011. Vol 55(1):192-206. HCV protease inhibitors (PI) Inhibit NS3/NS4A serine protease responsible for the processing of the polyprotein 1st generation 1st generation, 2nd wave 2nd generation Resistance low low high barrier Genotype activity 1: 1 a< 1b All except 3 all Drug drug Important Less Less interaction Drugs Boceprevir Simeprevir (Janssen) MK-5172 Telaprevir Faldaprevir (BI) ACH-2684 Paritaprevir (ABT-450)/r (AbbVie) Vedroprevir (Gilead) Vaniprevir (Merck) Sovaprevir (Achillion) Asunaprevir (BMS) NS3/NS4A structure Repositioning of helicase domain Self cleavage Lipid Bilayer Inactive Insertion of the Active carboxy-terminal tail Bartenschlager et al.
    [Show full text]
  • 2019 Icar Program & Abstracts Book
    Hosted by the International Society for Antiviral Research (ISAR) ND International Conference 32on Antiviral Research (ICAR) Baltimore MARYLAND PROGRAM and USA Hyatt Regency BALTIMORE ABSTRACTS May 12-15 2019 ND TABLE OF International Conference CONTENTS 32on Antiviral Research (ICAR) Daily Schedule . .3 Organization . 4 Contributors . 5 Keynotes & Networking . 6 Schedule at a Glance . 7 ISAR Awardees . 10 The 2019 Chu Family Foundation Scholarship Awardees . 15 Speaker Biographies . 17 Program Schedule . .25 Posters . 37 Abstracts . 53 Author Index . 130 PROGRAM and ABSTRACTS of the 32nd International Conference on Antiviral Research (ICAR) 2 ND DAILY International Conference SCHEDULE 32on Antiviral Research (ICAR) SUNDAY, MAY 12, 2019 › Women in Science Roundtable › Welcome and Keynote Lectures › Antonín Holý Memorial Award Lecture › Influenza Symposium › Opening Reception MONDAY, MAY 13, 2019 › Women in Science Award Lecture › Emerging Virus Symposium › Short Presentations 1 › Poster Session 1 › Retrovirus Symposium › ISAR Award of Excellence Presentation › PechaKucha Event with Introduction of First Time Attendees TUESDAY, MAY 14, 2019 › What’s New in Antiviral Research 1 › Short Presentations 2 & 3 › ISAR Award for Outstanding Contributions to the Society Presentation › Career Development Panel › William Prusoff Young Investigator Award Lecture › Medicinal Chemistry Symposium › Poster Session 2 › Networking Reception WEDNESDAY, MAY 15, 2019 › Gertrude Elion Memorial Award Lecture › What’s New in Antiviral Research 2 › Shotgun Oral
    [Show full text]